Depression and Functional Disability Mark Early Cardiovascular Risk in CKM Stages 0–3
Depression and functional disability each tracked with higher incident cardiovascular disease among adults in early cardiovascular-kidney-metabolic syndrome, and the burden was greatest when both were present. In a nationally representative cohort of 7,217 adults with CKM stages 0–3, the pattern was consistent across incident CVD, heart disease, and stroke.
The study matters because CKM staging is designed to identify cardiometabolic vulnerability before overt cardiovascular disease appears. Adding psychological distress and physical limitation to that framework shifts the focus from a purely laboratory-based risk model to one that better reflects what clinicians actually encounter at the bedside: patients whose cardiovascular risk is shaped not only by blood pressure, glucose, and kidney status, but also by mood, mobility, and day-to-day function.
A Joint Signal Across Mood, Function, and Vascular Outcomes
Participants were grouped according to baseline depression and functional disability status, then followed for cardiovascular outcomes. Those with depression only had higher risk than participants with neither condition. Functional disability alone carried a similar excess risk. The combined phenotype produced the highest risk of all.
The clinical message is direct. Depression and disability did not merely coexist with cardiometabolic disease; they identified a subgroup in which vascular events accumulated more readily. In practical terms, a patient in an early CKM stage who is also withdrawn, persistently low in mood, or limited in daily activities may sit on a steeper risk trajectory than traditional risk-factor screening would suggest.
Biologically, the association is plausible even without mechanistic measurements in this cohort. Depression can alter autonomic tone, sleep, physical activity, treatment adherence, and inflammatory signaling, while functional disability often marks reduced exercise capacity, frailty, sarcopenia, and social isolation. Each of those pathways can accelerate vascular injury and reduce resilience once atherosclerotic disease begins to develop.
Risk Was Higher Without Evidence of Interaction
The combined burden did not produce a statistically significant additive or multiplicative interaction between depression and functional disability. In plain terms, each factor raised risk, but the joint effect did not behave as a special synergistic mechanism beyond their separate contributions.
That finding is useful at the bedside. Depression should not be viewed as clinically relevant only when paired with severe disability, and disability should not be dismissed when mood symptoms are absent. Each condition deserves independent attention during cardiovascular risk assessment, because each appears to carry its own prognostic weight in early CKM disease.
This is where the CKM framework becomes more than a staging system. It becomes a screening opportunity. Patients in stages 0–3 are still early enough in the disease course that behavior change, mental health support, rehabilitation, and aggressive control of conventional risk factors may alter future trajectory. The study suggests that risk stratification becomes more precise when clinicians ask about function and mood with the same seriousness they apply to cholesterol or kidney markers.
Prediction Improved When Depression and Disability Were Added to Conventional Factors
Beyond outcome associations, the model performed modestly better when depression and functional disability were added to conventional risk factors. The improvement was not described as dramatic, but even a modest gain is meaningful in a population where early identification can change preventive strategy.
A small increase in predictive performance may still matter when it helps distinguish one patient from another in a broad at-risk cohort. That distinction can shape follow-up intensity, referral decisions, and how urgently a clinician addresses rehabilitation, mental health care, or secondary prevention. For a patient with CKM stage 1 or 2 disease, a missed psychosocial burden may translate into a missed opportunity to reduce downstream vascular events.
The findings also fit with a growing view of cardiovascular prevention as a multidimensional task. Traditional risk factors remain central, but they are not sufficient to describe risk in many older adults, especially when functional limitation and depression signal reduced physiologic reserve. In this cohort, those nontraditional factors were not peripheral; they were embedded in the event signal itself.
Why Early CKM Stages Need Broader Risk Assessment
CKM stages 0–3 represent a window before clinical cardiovascular disease becomes established. Once overt CVD appears, prevention becomes more constrained by prior injury and existing pathology. Before that point, the emphasis should be on identifying hidden risk that is already shaping long-term outcomes. Depression and functional disability fit that role because both are common, clinically visible, and potentially actionable.
The study does not prove that treating depression or reversing disability will lower cardiovascular events, and it does not measure whether intervention changes the observed risk gradient. Even so, it gives clinicians a reason to stop treating mood and mobility as separate from cardiovascular prevention. When both are present, the patient appears to occupy a higher-risk phenotype within the CKM spectrum.
What This Cohort Adds to Cardiovascular Prevention
The sample came from the China Health and Retirement Longitudinal Study, giving the analysis a nationally representative foundation and making the findings relevant to middle-aged and older adults in a real-world population. The outcomes were assessed over follow-up using fully adjusted Cox models, and the associations remained after accounting for conventional confounders.
The study’s central contribution is not that depression and disability are “new” risk factors. Their contribution is that they refine risk in a framework built to catch cardiovascular vulnerability earlier. For clinicians, the practical implication is straightforward: in adults with CKM stages 0–3, asking about mood and function is not an optional add-on. It belongs in the cardiovascular risk interview alongside standard metabolic assessment.
The unanswered question is whether targeted treatment of depression, structured rehabilitation, or combined interventions can shift outcomes in this CKM population. Until intervention data arrive, the current evidence supports a more complete risk assessment and a lower threshold to recognize psychological and functional vulnerability as part of cardiovascular care.